XM does not provide services to residents of the United States of America.

Blackstone explores sale of Anthos Therapeutics -sources



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Blackstone explores sale of Anthos Therapeutics -sources</title></head><body>

By David Carnevali

NEW YORK, Dec 4 (Reuters) -Private equity firm Blackstone Inc BX.N is exploring the sale of Anthos Therapeutics, a developer of a new generation of blood thinners it launched four years ago with backing from Novartis AG NOVN.S, according to people familiar with the matter.

Anthos, which does not generate any revenue because its products have not yet hit the market, could be worth several billion dollars in a potential sale, significantly more than the $250 million that Blackstone invested when it founded Anthos in 2019, the sources said. The company's anticoagulants have made significant progress in late-stage clinical trials, the sources added.

Cambridge, Massachusetts-based Anthos' most advanced product, a monoclonal antibody called abelacimab, is intended for patients with atrial fibrillation who do not respond well to other anticoagulants because of heavy bleeding.

Over 37 million people worldwide are diagnosed with atrial fibrillation, a heart malfunction that can lead to strokes or other deadly events, Anthos said last month, citing research studies.

Blackstone is working with investment bankers to explore a sale of Anthos, the sources said, cautioning that no deal is certain and requesting anonymity because the matter is confidential.

Blackstone declined to comment.

Anthos has licensed from Novartis an antibody used in the development of its blood thinners and granted it a minority stake.

Major players in the blood thinner drug space include Bristol-Myers Squibb BMY.N and Pfizer's PFE.N Eliquis and Bayer's BAYGn.DE Xarelto.

Bayer announced last month it would stop development of a next-generation blood thinner because of clinical setbacks. The German drug maker was counting on the product to generate an estimated $5.5 billion in peak sales and replace Xarelto when its patent expires in 2026. Eliquis' patent protection is also ending in the coming years.

Blackstone, which has over $1 trillion in assets under management, launched a dedicated life sciences investment arm after it acquired Clarus, an investment firm specializing in clinical trial deals, in 2018. Its bets since then have included investing more than $1 billion to back Alnylam Pharmaceuticals, which is developing drugs to tackle cholesterol and other diseases.



Reporting by David Carnevali in New York; Editing by Leslie Adler

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.